Literature DB >> 15180501

Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects.

Jiri Neuzil1, Marco Tomasetti, Albert S Mellick, Renata Alleva, Brian A Salvatore, Marc Birringer, Marc W Fariss.   

Abstract

In spite of unrelenting effort, the net incidence of neoplastic diseases appears not to have been curbed. While some types of cancer have been suppressed significantly, others are either stagnating or on the increase. Therefore, the need for a cure is imperative, in particularly a drug or combination of drugs that would be selective for malignant cells, i.e. with as low secondary toxicity as possible. Recent data strongly suggest that analogues of vitamin E, epitomised by the most studied alpha-tocopheryl succinate (alpha-TOS), may meet the need for the coveted drugs with a selective anti-neoplastic effect. The reasons for this optimism are reviewed in this article.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180501     DOI: 10.2174/1568009043332943

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  15 in total

1.  The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation.

Authors:  Yuhuan Li; Tobias Hahn; Kendra Garrison; Zhi-Hua Cui; Andrew Thorburn; Jacqueline Thorburn; Hong-Ming Hu; Emmanuel T Akporiaye
Journal:  Cancer Res       Date:  2012-06-28       Impact factor: 12.701

Review 2.  Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors.

Authors:  T Hahn; M J Polanczyk; A Borodovsky; L V Ramanathapuram; E T Akporiaye; S J Ralph
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

3.  α-Tocopheryl succinate induces apoptosis in erbB2-expressing breast cancer cell via NF-κB pathway.

Authors:  Xiu-fang WANG; Ying XIE; Hong-gang WANG; Yuan ZHANG; Xiao-cui DUAN; Zhan-jun LU
Journal:  Acta Pharmacol Sin       Date:  2010-12       Impact factor: 6.150

4.  Solubility of α-Tocopheryl Succinate in Supercritical Carbon Dioxide Using Offline HPLC-MS/MS Analysis.

Authors:  Brooks M Hybertson
Journal:  J Chem Eng Data       Date:  2007-05       Impact factor: 2.694

5.  alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate.

Authors:  M Tomasetti; E Strafella; S Staffolani; L Santarelli; J Neuzil; R Guerrieri
Journal:  Br J Cancer       Date:  2010-03-23       Impact factor: 7.640

6.  Orally active alpha-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer.

Authors:  Tobias Hahn; Karen Fried; Laurence H Hurley; Emmanuel T Akporiaye
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

7.  Enhancement in alpha-tocopherol succinate-induced apoptosis by all-trans-retinoic acid in primary leukemic cells: role of antioxidant defense, Bax and c-myc.

Authors:  K L Khanduja; S Kumar; N Varma; S C Varma; P K Avti; C M Pathak
Journal:  Mol Cell Biochem       Date:  2008-07-19       Impact factor: 3.396

Review 8.  Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II.

Authors:  Jiri Neuzil; Jeffrey C Dyason; Ruth Freeman; Lan-Feng Dong; Lubomir Prochazka; Xiu-Fang Wang; Immo Scheffler; Stephen J Ralph
Journal:  J Bioenerg Biomembr       Date:  2007-02       Impact factor: 3.853

9.  α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response.

Authors:  Tobias Hahn; Bhumasamudram Jagadish; Eugene A Mash; Kendra Garrison; Emmanuel T Akporiaye
Journal:  Breast Cancer Res       Date:  2011-01-13       Impact factor: 6.466

10.  Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced brain and retinal damages.

Authors:  Orhan Sezen; Mustafa Vecdi Ertekin; Berna Demircan; Ihsan Karslioğlu; Fazli Erdoğan; Ibrahim Koçer; Ilknur Calik; Akçahan Gepdiremen
Journal:  Neurosurg Rev       Date:  2008-02-08       Impact factor: 2.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.